Scottish startup 1nhaler secures £2.2M to replace bulky plastic inhalers with cardboard
1nhaler, a Scotland-based drug delivery device developer, has secured £2.2 million in follow-on funding to progress its novel pop-up cardboard inhaler towards first regulatory approval. Archangels led...
Scotland's 1nhaler startup has successfully obtained £2.2 million in follow-on funding to develop a novel pop-up cardboard inhaler, which aims to replace traditional bulky plastic inhalers. The investment was led by Archangels, with support from Scottish Enterprise and BBB Investments. The funds will be used to advance 1nhaler's lead product, 1nhaler Salbutamol, a combination of a unique inhalable device and a well-known asthma medication.
Inhalable medicines are currently used to treat a variety of conditions, including asthma, COPD, influenza, epilepsy, depression, and Parkinson's disease. 1nhaler's single-dose Directly-Portable-Inhaler (DPI) platform is made primarily from cardboard and is designed to be more user-friendly, cost-effective, and environmentally friendly compared to conventional inhalers typically made from plastic.
The funding will also enable 1nhaler to progress a small clinical trial, supported by manufacturing engineering studies, to obtain regulatory approval, which is expected by late 2027. Lisa McMyn, CEO of 1nhaler, expressed excitement about taking their lead product into clinical trials, while Archangels' Sarah Hardy highlighted the team's progress and the potential of the inhaler device to disrupt the global market for inhaled medicines.
Written by urgent.news from Tech.eu's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
